SMSandra Martineau

Sandra Martineau

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sandra Martineau has a total of 50 co-authors. Here are the top co-authors by number of shared publications:

  • François Potus

    Pulmonary Hypertension Research Group, Centre de Recherche de l’Institut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval, Quebec City, Quebec, Canada

    4 shared publications
  • Olivier Boucherat

    Centre de Recherche de l’Institut Universitaire de Cardiologie et de Pneumologie de Québec, Québec, QC, Canada (M.M., O.B., S.P., S.B., F.P.).

    4 shared publications
  • Steeve Provencher

    PAH Research Group, Institut Universitaire de Cardiologie et Pneumologie de Québec Research Center, Department of Medicine, Université Laval, Quebec City, Québec, Canada

    4 shared publications
  • Sébastien Bonnet

    Centre de Recherche de l’Institut Universitaire de Cardiologie et de Pneumologie de Québec, Québec, QC, Canada (M.M., O.B., S.P., S.B., F.P.).

    4 shared publications
  • Yann Grobs

    Pulmonary Hypertension Research Group, Centre de Recherche Universitaire de Cardiologie et de Pneumologie de Québec, Canada (Y.G., S.-E.L., M.M., C.T., M.B., S.B.-B., S.M., A.B., A.P., M.F., J.P., F.P., S.P., O.B., S.B.).

    4 shared publications
  • Manon Mougin

    Centre de Recherche de l’Institut Universitaire de Cardiologie et de Pneumologie de Québec, Québec, QC, Canada (M.M., O.B., S.P., S.B., F.P.).

    3 shared publications

Latest Publications

  • Exploring the Role of Hypusine Signaling in Vascular Smooth Muscle Cells for Mitigating Restenosis in Coronary Artery Disease

    by Yann Grobs, Sarah-Eve Lemay, Manon Mougin, Charlie Theberge, Magalie Boucher, Sandra Breuils-Bonnet, Sandra Martineau, Alice Bourgeois, Andreanne Pelletier, Maud Fillon, et al.

    BACKGROUND: Post-surgical restenosis in patients with coronary artery disease (CAD) is a pathological vascular remodeling process characterized by neointimal hyperplasia, which is mainly driven by phenotypic switching of vascular smooth muscle cells toward a synthetic and proliferative state. This study investigated a novel signaling pathway to promote the proproliferative phenotype of vascular smooth muscle cells and contribute to the neointimal hyperplasia development. METHODS: Using comparative proteomic analysis and Western blotting, expression of hypusine signaling components was evaluated in human primary cultures of coronary artery smooth muscle cells isolated from controls and patients with CAD, as well as in 3 preclinical animal models of restenosis: rat carotid injury, mouse carotid ligation, and canine coronary artery bypass graft. CAD-coronary artery smooth muscle cell proliferation was assessed by Western blot and immunofluorescence with pharmacological (N1-guanyl-1,7-diaminoheptane) and molecular (shRNA) inhibitors of DHPS (deoxyhypusine synthase). The contribution of hypusine signaling to neointimal hyperplasia was investigated using both pharmacological and genetic approaches. In addition, human saphenous vein and human coronary artery tissue cultures were used to explore the translational potential of targeting hypusine signaling to prevent neointimal hyperplasia. RESULTS: All components of the hypusine pathway (eIF5A (eukaryotic translation initiation factor 5A), DOHH (deoxyhypusine hydroxylase), and DHPS were significantly overexpressed in CAD-coronary artery smooth muscle cells and in preclinical animal models of restenosis. Pharmacological and molecular inhibition of DHPS reduced eIF5A hypusination, vascular smooth muscle cell proliferation, and expression of ECM (extracellular matrix) proteins. Proteomic and KEGG analyses demonstrated disruption of cell-cycle and DNA replication pathways, including a downregulation of TTK (threonine tyrosine kinase). Our findings suggest that TTK acts as a downstream effector of hypusine signaling, which partly mediates the proliferative effects observed in CAD-coronary artery smooth muscle cells. In vivo, pharmacological and smooth muscle cell–targeted inactivation of DHPS significantly reduced neointimal hyperplasia without adverse effects. Finally, ex vivo human tissue culture confirmed that N1-guanyl-1,7-diaminoheptane mitigates growth factor–induced vascular remodeling. CONCLUSIONS: Hypusine signaling is a critical regulator of vascular smooth muscle cell proliferation for neointimal hyperplasia. Inhibiting DHPS reduces vascular remodeling, making it a promising target for preventing restenosis after coronary interventions.

  • Open Access

    Breast Cancer Reveals Latent BMPR2 -Related Susceptibility to Pulmonary Hypertension

    by Victoria Toro, Manon Mougin, Coline Brossat, Clement Jambon-Barbara, Alex Hlavaty, Charles Antoine Guay, Reem El Kabbout, Coralie Bilodeau, Yann Grobs, Sandra Martineau, et al.

    BACKGROUND: Pulmonary arterial hypertension (PAH) and breast cancer disproportionately affect women. BMPR2 (bone morphogenetic protein receptor type 2) mutations, the most common genetic cause of heritable PAH, also exert tumor-suppressive functions, but their role in linking these diseases remains unclear. METHODS: We combined bioinformatic, epidemiologic, and experimental approaches. Public cancer datasets were mined for BMPR2 alterations. In vivo, mammary tumor development and pulmonary hemodynamics were assessed in female Bmpr2 +/Δ71 rats with or without carcinogen (7,12-dimethylbenz[a]anthracene) exposure. Pulmonary arterial smooth muscle cells were exposed to tumor-conditioned media to test inflammatory proliferation. Finally, associations between breast cancer and PAH were examined in the French National Healthcare Database (9964 patients with PAH). RESULTS: BMPR2 expression was markedly reduced in human breast tumors, with recurrent somatic variants and deep deletions identified. Bmpr2 +/Δ71 rats exhibited spontaneous mammary tumors and, following 7,12-dimethylbenz[a]anthracene exposure, developed exacerbated pulmonary hypertension with increased vascular remodeling and inflammation. Tumor-bearing Bmpr2 +/Δ71 rats showed elevated lung IL-1β and NF-κB activation. In vitro, conditioned media from Bmpr2 +/Δ71 tumors induced proliferation of Bmpr2 +/Δ71 pulmonary arterial smooth muscle cells via IL-1β–dependent signaling, while neutralization of IL-1β attenuated this effect. Human pulmonary arterial smooth muscle cells carrying BMPR2 mutations similarly displayed heightened IL-1β–induced proliferation. Epidemiologically, breast cancer incidence was more than doubled in patients with PAH compared with the general population, and PAH incidence was increased nearly 9-fold among patients with breast cancer, indicating a bidirectional relationship. CONCLUSIONS: These findings identify a reciprocal association between breast cancer and PAH mediated by defective BMPR2 signaling and tumor-associated inflammation. Breast cancer may act as a “second hit,” unmasking BMPR2 -related susceptibility to PAH, underscoring BMPR2 as a shared molecular vulnerability with implications for surveillance of at-risk populations.


  • Open Access

    Exploring the Role of Hypusine Signaling in Vascular Smooth Muscle Cells for Mitigating Restenosis in Coronary Artery Disease

    by Yann Grobs, Sarah-Eve Lemay, Manon Mougin, Charlie Theberge, Magalie Boucher, Sandra Breuils-Bonnet, Sandra Martineau, Alice Bourgeois, Andreanne Pelletier, Maud Fillon, et al.

    Background: Post-surgical restenosis in patients with coronary artery disease (CAD) is a pathological vascular remodeling process characterized by neointimal hyperplasia, mainly driven by vascular smooth muscle cells (VSMCs) phenotypic switching toward synthetic and proliferative state. This study identifies novel signaling pathway promoting pro-proliferative phenotype of VSMC and contributing to the neointimal hyperplasia development. Methods: The expression of hypusine signaling components was evaluated in human primary culture of coronary artery smooth muscle cells (CoASMCs) isolated from controls and patients with CAD, using comparative proteomic analysis and western blotting, as well as in three preclinical animal models of restenosis; rat carotid injury, mice carotid ligation and canine coronary artery bypass graft. CAD-CoASMCs proliferation was assessed by western blot and immunofluorescence with pharmacological (GC7) and molecular (shRNA) inhibitors of deoxyhypusine synthase (DHPS). The contribution of hypusine signaling to neointimal hyperplasia was investigated using both pharmacological and smooth muscle cell-specific knockout mice approaches. Additionally, human saphenous vein and human coronary artery tissue cultures were employed to explore the translational potential of targeting hypusine signaling to prevent neointimal hyperplasia. Results: All components of the hypusine pathway (eukaryote translational initiation factor 5A (eIF5A), deoxyhypusine hydroxylase (DOHH) and DHPS) were significantly overexpressed in CAD-CoASMCs and in preclinical animal models of restenosis. Pharmacological and molecular inhibition of DHPS reduced eIF5A hypusination, VSMC proliferation and expression of extracellular matrix proteins. Proteomic and KEGG analyses demonstrated disruption of cell cycle and DNA replication pathways, including a downregulation of threonine tyrosine kinase (TTK). Our findings suggest that TTK acts as a downstream effector of hypusine signaling, partly mediating to the proliferative effects observed in CAD-CoASMCs. In vivo , pharmacological and genetic inhibition of DHPS significantly reduced neointimal hyperplasia without adverse effects. Finally, ex vivo human tissue culture confirmed that GC7 mitigates growth factor–induced vascular remodeling. Conclusions: Hypusine signaling is a critical regulator of VSMC proliferation for neointimal hyperplasia. Inhibiting DHPS reduces vascular remodeling, making it a promising target for preventing restenosis after coronary interventions. Clinical Perspective: What Is New?: Hypusine signaling is markedly upregulated in coronary artery smooth muscle cells (CoASMCs) from patients with coronary artery disease (CAD) and in multiple preclinical models of restenosis. Proteomic profiling identifies DHPS, the rate-limiting enzyme for eIF5A hypusination, as a key driver of vascular smooth muscle cell (VSMC) pro-proliferative phenotype and extracellular matrix production. Pharmacological (GC7) and genetic inhibition of DHPS effectively suppress eIF5A hypusination, attenuate the synthetic and proliferative CAD-CoASMCs phenotype, and significantly reduce neointimal hyperplasia in rodent models of vascular injury. Ex vivo human tissue demonstrates that DHPS inhibition prevents neointimal hyperplasia, providing strong translational evidence. What Are the Clinical Implications?: These findings establish hypusine signaling as a previously unrecognized regulator of pathological VSMC activation in CAD and restenosis. DHPS inhibition emerges as a promising therapeutic strategy to prevent neointimal hyperplasia following coronary interventions such as angioplasty, stenting, or bypass grafting. Collectively, our data support the clinical development of selective DHPS inhibitors as a novel class of therapeutics to improve long-term outcomes after coronary revascularization and potentially other occlusive vascular diseases.

  • Top Cited Papers
    Open Access

    Exploring Integrin α5β1 as a Potential Therapeutic Target for Pulmonary Arterial Hypertension: Insights From Comprehensive Multicenter Preclinical Studies

    by Sarah-Eve Lemay, Mónica S. Montesinos, Yann Grobs, Tetsuro Yokokawa, Tsukasa Shimauchi, Manon Mougin, Charlotte Romanet, Mélanie Sauvaget, Sandra Breuils-Bonnet, Alice Bourgeois, et al.

    BACKGROUND: Pulmonary arterial hypertension (PAH) is characterized by obliterative vascular remodeling of the small pulmonary arteries (PAs) and progressive increase in pulmonary vascular resistance leading to right ventricular failure. Although several drugs are approved for the treatment of PAH, mortality rates remain high. Accumulating evidence supports a pathological function of integrins in vessel remodeling, which are gaining renewed interest as drug targets. However, their role in PAH remains largely unexplored. METHODS: The expression of the RGD (arginylglycylaspartic acid)–binding integrin α5β1 was assessed in PAs, PA smooth muscle cells, and PA endothelial cells from patients with PAH and controls using NanoString, immunoblotting, and Mesoscale Discovery assays. RNA sequencing was conducted to identify gene networks regulated by α5β1 inhibition in PAH PA smooth muscle cells. The therapeutic efficacy of α5β1 inhibition was evaluated using a novel small molecule inhibitor and selective neutralizing antibodies in Sugen/hypoxia and monocrotaline rat models, with validation by an external contract research organization. Comparisons were made against standard-of-care therapies (ie, macitentan, tadalafil) and sotatercept and efficacy was assessed using echocardiographic, hemodynamic, and histological assessments. Ex vivo studies using human precision-cut lung slices were performed to further assess the effects of α5β1 inhibition on pulmonary vascular remodeling. RESULTS: We found that the arginine-glycine-aspartate RGD-binding integrin α5β1 is upregulated in PA endothelial cells and PA smooth muscle cells from patients with PAH and remodeled PAs from animal models. Blockade of the integrin α5β1 or depletion of the α5 subunit downregulated FOXM1 (forkhead box protein M1)–regulated gene networks, resulting in mitotic defects and inhibition of the pro-proliferative and apoptosis-resistant phenotype of PAH cells. We demonstrated that α5β1 integrin blockade safely attenuates pulmonary vascular remodeling and improves hemodynamics and right ventricular function and matched or exceeded the efficacy of standard of care and sotatercept in multiple preclinical models. Ex vivo studies further validated its potential in reversing advanced remodeling in human precision-cut lung slices. CONCLUSIONS: These findings establish α5β1 integrin as a pivotal driver of PAH pathology and we propose its inhibition as a novel, safe, and effective therapeutic strategy for PAH.